Medical care's state of denial
Victoria Colliver, Chronicle Staff Writer
But what happens when that process breaks down and sick patients are left to fight for medical care?
Each year, thousands of Californians find themselves at odds with their health insurers over whether they, as patients, should get the treatment their doctors prescribed.
Peter Isgro of Santa Cruz is among them. His insurer, Anthem Blue Cross, stopped paying for certain chemotherapy drugs after his cancer progressed, a decision that has been upheld in two appeals.
Isgro said he feels like the insurance company is second-guessing his doctor. “If your doctor wants to give you something and they can deny it, that’s wrong,” he said.
Anthem Blue Cross said it follows strict protocols, relying on medical evidence in determining what is necessary and appropriate to cover.
“Even in a dire situation, it is ethically appropriate to withhold treatment if it’s not effective,” said Dr. Michael Belman, medical director of Anthem Blue Cross, who was not speaking specifically about Isgro’s case. Belman said doctors do not always recommend the best treatments, and cost is never a primary consideration.
Consumer advocates, however, see the situation differently.
Health insurers “are going back to the old strategies of the ’90s, when they interrupted care on the front end by denying or delaying treatment offered by a doctor,” said Jerry Flanagan, health advocate for Consumer Watchdog, a Santa Monica group. According to him, insurers hope patients will give up or settle for less, either way saving them money, a contention the companies dispute.
Patients now have a number of resources to turn to if they believe they received an unfair denial. Last year, the state’s HMO Help Center received nearly 90,000 calls from consumers asking for help in resolving their health plan woes.
About 7,000 Californians have taken advantage of third-party medical reviews since 2001, when the state Department of Managed Health Care started offering them. Last year, the department resolved 1,716 independent medical review, or IMR, cases.
The Department of Insurance, which regulates a smaller number of plans, received 35,280 complaints and resolved 262 IMRs in 2007.
About 40 percent of all IMR decisions are settled in favor of the patient, according to the Department of Managed Health Care.
The majority of treatment disputes address whether the proposed therapy is “medically necessary” or if it is considered to be “experimental” or “investigational.” Even treatments approved by the U.S. Food and Drug Administration can be deemed experimental if they are typically used in a different fashion or there is simply not enough evidence to support the use.
Physicians often feel caught in the middle.
“Do I stop treating them while the insurer determines they have eligibility? Even if they get authorization, they say that doesn’t guarantee payment,” said Dr. Michael Sherman, an oncologist who has offices in Walnut Creek and San Ramon. Sherman said he is forced to provide unreimbursed treatments to patients in those situations.
Dr. Alan Sokolow, chief medical officer for Blue Shield of California, said insurers try to strike a balance.
“We think that is our job – to help patients and providers apply the benefit package the patient has, the dollars they put for insurance coverage and health care, in the most appropriate and effective way,” he said, adding that patients should appeal if they disagree.
When appeals don’t work, patients can sue their health plan. But that can be a difficult proposition, given that it can be tough to get a lawyer to take such a case, and most plans require their members to agree to binding arbitration.
In the end, patients usually want to get the treatment rather than endure a lengthy legal process.
Joanna Smith, a patient advocate who runs Healthcare Liaison Inc. in Berkeley, said persistence and doing research to back up the case give patients a better chance of success.
“I always say to people appeal, appeal, appeal,” she said. “And then appeal again.”
Case studies: Three Northern California patients’ struggles with insurance carriers. A15
In December 2006, when Karen Vinci’s bile-duct cancer recurred, she was told surgery wasn’t an option because of the location of the tumor.
Instead, a group of doctors at UCSF recommended what they considered the Alamo woman’s only option: five weeks of external-beam radiation followed by noninvasive radiosurgery that used a robotic device called CyberKnife, which attacks the tumor with high doses of targeted radiation.
Vinci’s insurer, Blue Shield, approved all the treatments she needed in preparation for the therapy, including the implantation of gold seeds in the tumor. But about two weeks into the radiation treatments in March 2007, Blue Shield reneged on the rest of the radiation as well her CyberKnife procedures.
So Vinci’s husband pulled out a checkbook and paid UCSF $10,000 of the $60,000 treatment to make sure his wife’s care was not delayed or canceled.
“I had no choice. It was either die or give them money,” said Vinci, 57.
Blue Shield had labeled the treatment, which received FDA approval in 2001 for treatment of nonoperable tumors in all parts of the body, “experimental.” CyberKnife’s manufacturer, Accuray Inc., said the federal government’s Medicare program covers the treatment, which has been used on more than 40,000 patients.
Vinci, with the help of her husband and a patient advocate at UCSF, immediately filed a grievance to have a doctor within the insurance company review her case. After that was denied, Vinci went to the insurer’s second-level appeal, a three-party panel, which sided with the company.
When Vinci requested an expedited independent medical review of her case through the Department of Managed Health Care, she got the answer she wanted. The state’s reviewers overturned Blue Shield’s decision, and the hospital promptly refunded the Vincis’ money.
Vinci, who is now cancer-free, still does not understand the denial, especially because the treatment was expected to give her a full recovery.
“It was just devastating to know that money was an issue when it comes to your life,” she said.
Richard Reynolds’ health insurer, Blue Shield of California, paid for virtually everything – surgery, chemotherapy, radiation and medication – after the Berkeley man was diagnosed last year with a rare form of cancer.
When his tumor failed to show on a standard CT scan, his doctors recommended a more sensitive and expensive imaging technique called a PET scan. But his medical group and insurer, having denied an earlier PET scan request, again balked, labeling the tool “experimental” or “investigational” for his diagnosis.
Reynolds managed to get the scan covered when his surgeon appealed directly to high-ranking Blue Shield executives. But a follow-up scan requested several months later was still denied.
Fearing a delay in care, Reynolds shelled out $2,200 in March for the scan at a private PET imaging center. CT scans cost about half the price of PET scans.
Reynolds was mystified by Blue Shield’s position. “They’ve paid for all kinds of specialists. They’ve put out hundreds and thousands of dollars. But with this one thing – the PET scan – they’ve drawn this bizarre line in the sand,” said Reynolds, 64, communications director at Mother Jones magazine.
His doctor recently submitted a fourth request for an upcoming PET scan, which also was denied.
Reynolds, whose appeals were initially denied through Blue Shield’s internal grievance process, submitted a request for an independent medical review through the state Department of Managed Health Care. But when a reporter told Blue Shield officials about the issue – even without identifying the patient or his diagnosis – they tracked down Reynolds’ case and resolved the problem.
Blue Shield’s medical director, Dr. Alan Sokolow, said his company should have covered the test, but found itself in the difficult terrain of trying to apply standardized protocols to a rare condition.
“We try very hard to be consistent and be fair and correct in our decision making. But this is why we have an appeal process,” he said. “Sometimes, we don’t always make the correct decision.”
When antiques store owner Peter Isgro was diagnosed with late-stage colon cancer, he was told he had just months to live. That was more than two years ago.
For those two additional years, the 61-year-old Santa Cruz resident credits a different oncologist who put him on an intense chemotherapy regimen – a multidrug concoction of older and cutting-edge therapies that costs about $10,000 every other week.
It was a treatment that gave Isgro the ability to continue working four days a week, allowed him to travel to Europe and kept him alive.
But after scans showed his tumors were growing, his insurer, Anthem Blue Cross, discontinued coverage of the more expensive drugs in his chemotherapy regimen. Since their use was stopped in early May, Isgro’s disease, according to his oncologist, has “exploded.”
“Clearly, we were keeping a lid on it. It was progressing very slowly and, when we stopped the drugs, it progressed very quickly,” said Dr. James Cohen of Los Gatos, adding that all of the drugs he had been combining are approved by the U.S. Food and Drug Administration for colon cancer.
Cohen said no amount or combination of medication would cure Isgro. Rather, he hoped to give him a better quality of life as well as more time.
Two appeals to the state Department of Managed Health Care have gone in favor of the insurer. In the most recent decision, issued June 12, two of the three reviewers concluded that the requested therapy would not be more beneficial than the standard, less expensive treatment the insurance company approved.
Isgro believes his insurer simply doesn’t want to spend any more money to keep him alive. And he’s angry.
“If my name was Kennedy, do you think they’d try to deny me?” he said, referring to Sen. Edward Kennedy, who recently underwent surgery for brain cancer.
Isgro, who has found an attorney to represent him at no cost, is considering his options. He recently resumed the more expensive treatments with the help of his sister, who paid more than $4,000 out of pocket. He also is contacting the pharmaceutical companies that make his drugs to see if they will help pay for his therapy.
“What good does it do to have any kind of national health care plan or state health care plan if your doctor, your primary doctor, does not have the right to prescribe the medications he feels are best for you?” he said. “That’s not health care.”
What to do if you are denied medical care
If your health insurance carrier is refusing to approve treatment recommended by your doctor, you have a number of options. First, contact your health plan. You probably will have to go through the plan’s internal grievance process first. If time is of the essence, ask for an expedited review through the state.
Tips to help you get the care you need:
— Review your health plan policy. Many are available online.
— Make sure your doctor is aware of your problem. Sometimes the initial denial comes from the medical group, which is charged with managing costs. In any case, your doctor’s support is important.
— Request the reason for the denial in writing. Take detailed notes of all conversations, including the date and time of the call and the name of the person you speak with. Save copies of all paperwork, and keep these records in chronological order.
— Act soon. If you wait longer than six months, you could lose the right to file a complaint, ask for an independent medical review (also called an IMR), or take other action against your health plan such as arbitration or a lawsuit. An IMR decision is binding on the health plan, but not the patient.
Source: Department of Managed Health Care; Kaiser Family Foundation; Healthcare Liaison Inc.; Chronicle research
E-mail Victoria Colliver at firstname.lastname@example.org.